Immunotech Biopharm Ltd (HKG:6978)
Hong Kong
· Delayed Price · Currency is HKD 2.450
+0.090 (3.81%)
At close: Mar 10, 2026
Immunotech Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Selling, General & Admin | 41.14 | 44.54 | 53.22 | 97.71 | 104.25 | 68.63 | Upgrade
|
| Research & Development | 130.57 | 154.24 | 177.33 | 176.22 | 240.61 | 278.63 | Upgrade
|
| Other Operating Expenses | 1.8 | 2.12 | 0.5 | 0.29 | 0.29 | 0.47 | Upgrade
|
| Operating Expenses | 173.5 | 200.9 | 231.05 | 274.22 | 345.15 | 347.72 | Upgrade
|
| Operating Income | -173.5 | -200.9 | -231.05 | -274.22 | -345.15 | -347.72 | Upgrade
|
| Interest Expense | -6.99 | -7.49 | -8.52 | -6.14 | -3.68 | -2.39 | Upgrade
|
| Interest & Investment Income | 0.98 | 1.07 | 3.01 | 3.2 | 7.56 | 3.65 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.17 | 0.22 | -0.07 | 0.09 | -6.27 | -40.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -19.95 | 60.39 | -9.23 | -5.62 | 10.51 | -35.23 | Upgrade
|
| EBT Excluding Unusual Items | -199.3 | -146.71 | -245.85 | -282.69 | -337.03 | -422.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | -23.07 | -19.81 | -90.01 | -24.02 | -18.79 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | -0.04 | 0.2 | -0.64 | -0.09 | 0.08 | Upgrade
|
| Asset Writedown | -19.88 | -19.88 | - | - | 1.3 | - | Upgrade
|
| Other Unusual Items | 19.34 | 0.02 | 0.19 | -13.75 | - | -16.98 | Upgrade
|
| Pretax Income | -222.89 | -186.42 | -335.48 | -321.1 | -354.62 | -439.13 | Upgrade
|
| Income Tax Expense | 0.93 | 0.93 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -223.82 | -187.34 | -335.48 | -321.1 | -354.62 | -439.13 | Upgrade
|
| Minority Interest in Earnings | 0.32 | 0.43 | 0.66 | 2.99 | 0.39 | 0.08 | Upgrade
|
| Net Income | -223.5 | -186.91 | -334.82 | -318.11 | -354.22 | -439.05 | Upgrade
|
| Net Income to Common | -223.5 | -186.91 | -334.82 | -318.11 | -354.22 | -439.05 | Upgrade
|
| Shares Outstanding (Basic) | 515 | 515 | 515 | 515 | 515 | 444 | Upgrade
|
| Shares Outstanding (Diluted) | 515 | 515 | 515 | 515 | 515 | 444 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | 15.95% | 16.82% | Upgrade
|
| EPS (Basic) | -0.43 | -0.36 | -0.65 | -0.62 | -0.69 | -0.99 | Upgrade
|
| EPS (Diluted) | -0.43 | -0.36 | -0.65 | -0.62 | -0.69 | -0.99 | Upgrade
|
| Free Cash Flow | -107.93 | -153 | -183.21 | -249.07 | -400.67 | -288.7 | Upgrade
|
| Free Cash Flow Per Share | -0.21 | -0.30 | -0.36 | -0.48 | -0.78 | -0.65 | Upgrade
|
| EBITDA | -115.68 | -141.6 | -178.83 | -231.11 | -324.33 | -333.99 | Upgrade
|
| D&A For EBITDA | 57.83 | 59.3 | 52.22 | 43.11 | 20.82 | 13.74 | Upgrade
|
| EBIT | -173.5 | -200.9 | -231.05 | -274.22 | -345.15 | -347.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.